Temporal expression profile of CXC chemokines in serum of patients with spinal cord injury
Temporal expression profile of CXC chemokines in serum of patients with spinal cord injury
复制标题
DOI：
10.1016/j.neuint.2013.07.012
复制
发表时间：
2013-11-01
影响因子：
4.2
通讯作者：
Taheri, Saeid
中科院分区：
文献类型：
--
作者：
Hassanshahi, Gholamhossein;Amin, Masoud;Taheri, Saeid
趋化因子是细胞因子超家族的一个亚类，具有促炎和迁移作用，在脊髓损伤（SCI）后的炎症反应中作为免疫细胞的趋化剂。趋化因子，尤其是CXCL-1、CXCL-9、CXCL-10和CXCL-12在脊髓损伤的炎性继发性损伤中起重要作用。抑制趋化因子的活性，从而继发性损伤级联已被认为是一种以趋化因子为靶点的脊髓损伤治疗方法。为了通过靶向趋化因子治疗优化对继发性损伤的抑制，需要准确了解这些细胞因子在脊髓损伤后的时间分布。因此，本研究计划在男性和女性SCI患者（n = 78）中测定脊髓损伤后3-6小时、7、28天和3 m时血清中CXCL-1、CXCL-9、CXCL-10和CXCL-12的水平，并与年龄和性别匹配的非脊髓损伤患者（NSCI, n = 70）和健康志愿者（n = 100）进行比较。采用方差分析和Tukey事后分析来确定组间的差异。本研究数据显示，血清中CXCL-1、CXCL-9和CXCL-10水平在脊髓损伤后第7天达到峰值，随后下降至对照水平。相比之下，脊髓损伤后CXCL-12水平的显著升高持续28天。此外，我们发现CXCL-12在脊髓损伤后的表达是性别依赖的。与对照组和女性SCI患者相比，男性SCI患者CXCL-12表达明显升高。我们未观察到NSCI的趋化因子水平有任何变化。此外，患者的年龄不影响脊髓损伤后趋化因子的表达。这些观察结果以及SCI诱导的csf趋化因子水平将有助于确定SCI后选择性和暂时性趋化因子靶向治疗。(C) 2013 Elsevier Ltd.版权所有。
Chemokines, a subclass of cytokine superfamily have both pro-inflammatory and migratory role and serve as chemoattractant of immune cells during the inflammatory responses ensuing spinal cord injury (SCI). The chemokines, especially CXCL-1, CXCL-9, CXCL-10 and CXCL-12 contribute significant part in the inflammatory secondary damage of SCI. Inhibiting chemokine's activity and thereby the secondary damage cascades has been suggested as a chemokine-targeted therapeutic approach to SCI. To optimize the inhibition of secondary injury through targeted chemokine therapy, accurate knowledge about the temporal profile of these cytokines following SCI is required. Hence, the present study was planned to determine the serum levels of CXCL-1, CXCL-9, CXCL-10 and CXCL-12 at 3-6 h, 7 and 28 days and 3 m after SCI in male and female SCI patients (n = 78) and compare with age- and sex-matched patients with non-spinal cord injuries (NSCI, n = 70) and healthy volunteers (n = 100). ANOVA with Tukey post hoc analysis was used to determine the differences between the groups. The data from the present study show that the serum level of CXCL-1, CXCL-9 and CXCL-10 peaked on day 7 post-SCI and then declined to the control level. In contrast, significantly elevated level of CXCL-12 persisted for 28 days post SCI. In addition, post-SCI expression of CXCL-12 was found to be sex-dependent. Male SCI patients expressed significantly higher CXCL-12 when compared to control and SCI female. We did not observe any change in chemokines level of NSCI. Further, the age of the patients did not influence chemokines expression after SCI. These observations along with SCI-induced CSF-chemokine level should contribute to the identification of selective and temporal chemokine targeted therapy after SCI. (C) 2013 Elsevier Ltd. All rights reserved.